BPC-157 — Pentadecapeptide Body Protection Compound

Dashboard at a glance

BPC-157 is a synthetic 15-amino-acid peptide (sequence: GEPPPGKPADDAGLV) derived from a protein found in human gastric juice. It is a research compound with no approved human indication anywhere in the world — but it has one of the more active preclinical literature records of any research peptide: 20+ cataloged findings spanning tendon, muscle, bone, gut, blood vessels, and the nervous system, plus three small published human pilots as of 2026.

Most of the evidence is from rodent studies, heavily concentrated in one research group. The three human pilots (knee pain, interstitial cystitis, and an IV safety study) are uncontrolled and tiny, so translation to proven human benefit has not been established. This dashboard organizes the data by evidence type — green for established mechanisms, amber for preclinical-only findings, blue for human data, red for regulatory caveats — so the state of the evidence is visible at a glance.

For a plain-English account of what people report when they use BPC-157 in research contexts, see the effects page.

What is BPC-157?

BPC-157 is a 15-amino-acid peptide (pentadecapeptide) with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — abbreviated GEPPPGKPADDAGLV. It is derived from a naturally occurring protective protein found in human gastric juice. Molecular weight: 1419.5 Da. Synonyms in the literature include Pentadecapeptide BPC 157, PL 14736, and Bepecin.

BPC-157 has no approved indication in any regulatory jurisdiction. It is classified as a research chemical and is listed by the World Anti-Doping Agency (WADA) under S0 — Non-Approved Substances, prohibited at all times.

The compound is notable for two properties that make it an active area of preclinical inquiry. First, it demonstrates gastric acid stability — a rare characteristic for a therapeutic peptide, enabling per-oral delivery without protective formulation. Second, it exhibits pleiotropic cytoprotective activity: the same peptide has been studied across musculoskeletal, gastrointestinal, vascular, and neurological injury models, with consistent findings of accelerated recovery versus untreated controls ^[4][20].

The Evidence at a Glance

Twenty distinct preclinical findings are cataloged in this dashboard, spanning rat, rabbit, beagle dog, pig, and two categories of human pilot study. The evidence distributes as follows:

Mechanistically established (green): Eight signaling pathways with multi-paper preclinical support — VEGFR2-Akt-eNOS, ERK1/2, FAK-paxillin, growth hormone receptor upregulation, NF-kB modulation, dopaminergic/serotonergic system interaction, context-dependent NO synthesis, and VEGF/CD34 upregulation ^{[1][2][7][9][10]}.

Preclinical-only / open question (amber): Tissue repair findings across tendon ^[1][2], ligament ^[3], wound/burn ^[4], muscle ^[5][18], and bone ^[6] consistently favor BPC-157 in rodent models. Independent replication outside the primary Zagreb-based research group remains limited.

Human data (blue): Three published pilot studies exist as of 2026. The knee pain study (n=16) reported 87.5% significant pain relief at 6–12 months ^[16]. The interstitial cystitis study (n=12) reported 80–100% symptom resolution at 6 weeks ^[15]. The IV safety pilot (n=2) reported no adverse events and plasma clearance within 24 hours ^[14].

Regulatory caveat (red): No FDA IND is currently active. No EMA approval exists. WADA S0 prohibition applies. No randomized controlled trials have been published.

Primary Research Questions This Site Addresses

This dashboard is organized around the questions most often posed in the BPC-157 research literature:

Mechanism: What molecular pathways does BPC-157 activate, and in which tissues? The /research page covers all eight documented pathways and the pathway-by-tissue evidence matrix.

Pharmacokinetics: What is BPC-157's plasma half-life, bioavailability by route, and peak concentration timing? These parameters are documented from formal PK studies in rats and beagle dogs ^[11]. The /dosage page presents the full PK dataset.

Human evidence: Three published pilot studies provide the first human data — limited in sample size and study design, but documented. Each is categorized with blue-coded evidence markers throughout this site.

Regulatory status: BPC-157 is not approved for human consumption in any country. Its WADA prohibition status, DoD prohibited ingredient designation, and the state of completed and registered clinical trials are covered on the /faq page.

How to Read This Dashboard

Every page in this site uses a four-color categorical system to mark the strength and type of evidence:

• Green — Mechanism established; pathway findings with support from multiple peer-reviewed papers.
• Amber — Preclinical only or open question; rodent and rabbit findings without confirmed human replication, or single-group results.
• Red — Regulatory or WADA caveat; not FDA approved, WADA S0 prohibited, DoD banned, or findings from single small pilots without RCT confirmation.
• Blue — Human data; reserved exclusively for the three published human pilot studies to keep the human-vs-animal evidence distinction visually unambiguous.

All dose values, half-life figures, bioavailability percentages, and citation numbers are rendered in monospace type — a typographic convention that marks the data layer as distinct from the prose layer. Every quantitative claim cites a specific study from the references index.